Pharmacetical Newswire

Pharmaceutical News!

Press release distribution service
Pharmaceutical Links

Pharmanewswire.Com: Pharmaceutical News

Bone Cancer Diagnosis Market Forecast & Future Industry Trends 2028

(PharmaNewsWire.Com, October 20, 2021 )



Market Overview

Bone cancer is rare cancer that develops when cells in the bone begin to grow out of control. The pelvis, long bones in the arms and legs are the most usually affected. Bone cancer is extremely rare, accounting for less than 1% of all cancers. Bone tumors that aren't cancerous are far more common than cancerous ones.



View full report: https://www.datamintelligence.com/research-report/bone-cancer-diagnosis-market



Market Dynamics

The factors affecting the global bone cancer diagnosis market are the rising population of children and young adults and technological advancements.



Rising population of children and young adults is expected to drive the global bone cancer diagnosis market



According to the American Cancer Society, between the ages of 10 and 30, most osteosarcomas develop in children, teenagers, and young adults. Although teenagers are the most typically affected age group, osteosarcoma can affect anyone at any age.



Osteosarcomas affect about one out of every ten adults over the age of 60. About 2% of childhood cancers are osteosarcomas. Children with osteosarcoma aged 0 to 14 had a 5-year survival rate of 68 percent. The 5-year survival rate for teenagers aged 15 to 19 is 67 percent. The overall 5-year survival rate for people of all ages is 74 percent if osteosarcoma is discovered and treated before it has progressed outside the location where it began.



The 5-year survival rate is 66 percent if the disease has migrated outside of the bones and into surrounding tissues or organs, as well as regional lymph nodes. The 5-year survival rate is 27 percent if cancer has progressed to other regions of the body. Teenage boys are the most common victims of osteosarcoma. Osteosarcoma patients are typically tall for their age, implying that the disease is caused by rapid bone growth.



Osteosarcoma is more common in children who have inherited one of the uncommon cancer syndromes. Retinoblastoma (a malignant tumour that forms in the retina, a portion of the eye, generally in children under the age of 2) and Li-Fraumeni syndrome (a type of inherited genetic mutation or change in a person's genes) are two of these syndromes.



There are 1.2 billion teenagers in the world today, accounting for one-sixth of the worldwide population. This figure is predicted to climb through 2050, especially in low- and middle-income nations, where about 90% of children aged 10 to 19 live. Hence, the increasing incidence of osteosarcoma and the rising population of teenagers is estimated to drive the global bone cancer diagnosis market.



Market Segmentation:

By Disease Type

• Osteosarcoma

• Chondrosarcoma

• Ewing’s sarcoma

By Diagnosis type

• MRI

• CT Scan

• X-ray

• Bone scan

• Biopsy

By End-User

• Hospitals

• Diagnostic Centers

• Cancer Research Centers



Download free sample: https://www.datamintelligence.com/download-sample/bone-cancer-diagnosis-market



Geographical Analysis

North America region accounted for the largest market share in the global bone cancer diagnosis market



The increasing incidence of osteosarcoma and companies launching new devices for cancer diagnosis is expected to increase this region's market growth.



In the United States, roughly 1,000 new instances of osteosarcoma are diagnosed each year. The majority of these are children and teenagers. Primary bone sarcoma will be diagnosed in an expected 3,610 people in the United States this year (2,100 men and boys and 1,510 women and girls). Around 400 of these instances are expected to occur in people aged 15 to 19 by 2020.



This disease is expected to kill 2,060 people this year (1,190 men and boys and 870 women and girls).



On February 17, 2020, Hyperfine, a New York City-based firm with offices in St Guilford and New York City, has received FDA approval for the first MRI scanner that can be wheeled to the patient's bedside.



In 2018, The Ingenia Ambition X 1.5T MR was released by Ingenia, a global pioneer in health technology. This exciting new advancement is the newest addition to the Ingenia MRI portfolio, which includes completely digital MRI equipment, healthcare informatics, and a variety of maintenance and life cycle services for integrated solutions that enable a faster, smarter, and simpler approach to a confident diagnosis. For a step-change in productivity, Ingenia Ambition X combines fully sealed BlueSeal magnet technology with workflow advancements.



Competitive Landscape

The global cancer diagnosis market is highly competitive with technological advancements and increased medical device launches with advanced technology by companies.



Some of the key players in the global bone cancer diagnosis market are Siemens Healthineers, Varex Imaging, Philips Healthcare, GE Healthcare, FUJIFILM Healthcare, Konica Minolta, Hologic, Leica Biosystems, Toshiba, and Shimadzu Corporation.



Topic's you may be interested, Ultrasound Simulation Market, Contrast Media Injectors Market, Breast Cancer Screening and Diagnostic Techniques Market, In-vitro Cancer Diagnostics Market, Mammography Detectors Market

DataM Intelligence

Sai Kiran

+1 877 441 4866

pr@datamintelligence.com

Source: EmailWire.Com

Source: EmailWire.com


Pharmaceutical Sponsors

Free Biotech & Pharmaceutical Magazines

Pharmacy Newswire Video Feed

Pharmaceutical & Biotech Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:

IronPort Provides Email Management and Analysis for a Premier Health Care Solutions Provider
Pharmaceutical & Medical Packaging News
Medical Laboratory Observer

No credit cards, coupons, or promo codes required. Try it today!

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com, or contact us.
Copyright 2009 GroupWeb Media LLC
GroupWeb Media Network

Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | i-SoftwareNews.com | iT-NewsWire.Com
| i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net
Pharmanewswire.com - Pharmaceutical Newswire and Press Release service of GroupWeb Media LLC